Overview

Salvational Intervention for Reducing AECOPD Under Severe Air Pollution

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, prospective, randomized and standard treatment parallel control clinical trial.A total of 764 stable COPD patients according to GOLD will be recruited and equally divided into two parallel groups, salvational intervention group (SI group) and control group (CT group).On the foundation of basic medicine, inhaled ICS/LABA will be used as an intervention drug for patients in SI group on severe air pollution days. It is aimed to evaluate whether this novel treatment strategy will decrease the frequency of AECOPD per year.
Phase:
N/A
Details
Lead Sponsor:
Peking University First Hospital
Collaborators:
Aerospace 731 Hospital
Beijing Changping Hospital
Beijing Jingmei Group General Hospital
Beijing Jishuitan Hospital
Beijing Luhe Hospital
Beijing Miyun Hospital
Civil Aviation General Hospital
Peking University Shougang Hospital
People's Hospital of Beijing Daxing District
People’s Hospital of Beijing Daxing District
The Hospital of Shunyi District Beijing
Treatments:
Bromides
Budesonide
Budesonide, Formoterol Fumarate Drug Combination
Formoterol Fumarate
Tiotropium Bromide